Enhanced external counterpulsation (EECP) decreases advanced glycation end products and proinflammatory cytokines in patients with non-insulin-dependent type II diabetes mellitus for up to 6 months following treatment.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Enhanced external counterpulsation (EECP) is a noninvasive, non-pharmacologic intervention proven to increase nitric oxide bioavailability in patients with coronary artery disease. The purpose of the present study was to evaluate the potential clinical benefits of EECP on advanced glycation end products (AGEs) and proinflammatory cytokine concentrations in patients with a clinical diagnosis of type II diabetes mellitus (T2DM).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Acta Diabetol

Title: Acta diabetologica

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1432-5233

ISSN (Print): 0940-5429

Publication date (Electronic): Oct 2016

Volume: 53

Issue: 5

Affiliations

[1 ] Department of Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, Gainesville, FL, 32611, USA. psardina@hhp.ufl.edu.

[2 ] Department of Cell Biology and Physiology, Edward Via College of Osteopathic Medicine, Auburn Campus, Auburn, AL, 36832, USA.

[3 ] School of Kinesiology, Auburn University, Auburn, AL, 36849, USA.

[4 ] Department of Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, Gainesville, FL, 32611, USA.

Article

Publisher Item ID: 10.1007/s00592-016-0869-6

DOI: 10.1007/s00592-016-0869-6

PubMed ID: 27278477

SO-VID: c2a901d3-cfc6-458c-9a35-b44350ddc872

History

Keywords: Advanced glycation end products,Proinflammatory cytokines,Type II diabetes,Enhanced external counterpulsation

Data availability:

Keywords: Advanced glycation end products, Proinflammatory cytokines, Type II diabetes, Enhanced external counterpulsation

Enhanced external counterpulsation (EECP) decreases advanced glycation end products and proinflammatory cytokines in patients with non-insulin-dependent type II diabetes mellitus for up to 6 months following treatment.

Read this article at

Abstract

Related collections

Special issue: Considering EU External Relations After Brexit

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 119

Cited by 4